- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/285 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
Patent holdings for IPC class C07K 14/285
Total number of patents in this class: 135
10-year publication summary
|
17
|
10
|
15
|
9
|
7
|
8
|
11
|
14
|
6
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1646 |
15 |
| Engineered Antigens Inc. | 10 |
6 |
| Serimmune Inc. | 19 |
6 |
| Research Institute at Nationwide Children's Hospital | 560 |
4 |
| Vaxxinova US, Inc. | 51 |
4 |
| Biotechnology Research and Development Corporation | 13 |
3 |
| University of Southern California | 2113 |
3 |
| Duke University | 3067 |
3 |
| Arne Forsgren et AL | 4 |
3 |
| CEVA Sante Animale | 697 |
3 |
| Merial, Inc. | 220 |
3 |
| The United States of America, as represented by the Secretary of Agriculture | 1102 |
3 |
| Boehringer Ingelheim Animal Health USA Inc. | 420 |
3 |
| Vaxcyte, Inc. | 49 |
3 |
| Eidgenossische Technische Hochschule Zurich | 98 |
2 |
| Imperial College Innovations Limited | 586 |
2 |
| Infectious Disease Research Institute | 45 |
2 |
| Limmatech Biologics AG | 20 |
2 |
| Nationwide Children's Hospital, Inc. | 78 |
2 |
| Regents of the University of Minnesota | 2696 |
2 |
| Other owners | 61 |